Haili Bio director fails to execute share reduction plan

Shanghai Hile Bio-Technology (SSE:603718) announced that Director and General Manager Han Benyi's share reduction plan concluded on June 13, 2025, without any shares being sold. The plan, initially announced on February 20, 2025, permitted Han Benyi to reduce his holdings by up to 682,500 shares, representing 0.1041% of the company's total share capital. Han Benyi currently holds 2,730,000 shares, or 0.4164% of Shanghai Hile Bio-Technology. The company confirmed that the actual reduction situation aligned with the previously disclosed plan.